Literature DB >> 12667643

Inhibition of C1q-beta-amyloid binding protects hippocampal cells against complement mediated toxicity.

M Sárvári1, I Vágó, C S Wéber, J Nagy, P Gál, M Mák, J P Kósa, P Závodszky, T Pázmány.   

Abstract

Activation of complement by beta-amyloid (A beta) contributes to the pathology of Alzheimer's disease (AD). Here, we show that C1-Inhibitor (C1-Inh) protects cultured rat hippocampal cells against beta-amyloid induced complement lysis indicating a classical pathway-mediated activation mechanism. We report on screening of compound libraries to identify compounds that inhibit C1q binding to beta-amyloid. Characterization of these compounds revealed that C1q possessed distinct binding sites for beta-amyloid and antibodies. One selected compound protected cultured hippocampal cells against complement-dependent beta-amyloid toxicity. These results provide evidence that complement has the potential to damage hippocampal cells, and C1q is a relevant target to suspend this deleterious mechanism in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12667643     DOI: 10.1016/s0165-5728(03)00040-7

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  11 in total

1.  Highly specific inhibition of C1q globular-head binding to human IgG: a novel approach to control and regulate the classical complement pathway using an engineered single chain antibody variable fragment.

Authors:  Hee Young Hwang; Marcus R Duvall; Stephen Tomlinson; Robert J Boackle
Journal:  Mol Immunol       Date:  2008-03-03       Impact factor: 4.407

2.  Development of a humanized C1q A chain knock-in mouse: assessment of antibody independent beta-amyloid induced complement activation.

Authors:  Ming Li; Rahasson R Ager; Deborah A Fraser; Natalia O Tjokro; Andrea J Tenner
Journal:  Mol Immunol       Date:  2008-04-08       Impact factor: 4.407

Review 3.  The role of glial cells and the complement system in retinal diseases and Alzheimer's disease: common neural degeneration mechanisms.

Authors:  Hannah Harvey; Szonya Durant
Journal:  Exp Brain Res       Date:  2014-09-03       Impact factor: 1.972

Review 4.  Kainic acid-mediated excitotoxicity as a model for neurodegeneration.

Authors:  Qun Wang; Sue Yu; Agnes Simonyi; Grace Y Sun; Albert Y Sun
Journal:  Mol Neurobiol       Date:  2005       Impact factor: 5.590

5.  Reaction of complement factors varies with prion strains in vitro and in vivo.

Authors:  Rie Hasebe; Gregory J Raymond; Motohiro Horiuchi; Byron Caughey
Journal:  Virology       Date:  2012-01-03       Impact factor: 3.616

Review 6.  Fundamental role of C1q in autoimmunity and inflammation.

Authors:  Myoungsun Son; Betty Diamond; Frances Santiago-Schwarz
Journal:  Immunol Res       Date:  2015-12       Impact factor: 2.829

7.  Alzheimer's Disease: APP, Gamma Secretase, APOE, CLU, CR1, PICALM, ABCA7, BIN1, CD2AP, CD33, EPHA1, and MS4A2, and Their Relationships with Herpes Simplex, C. Pneumoniae, Other Suspect Pathogens, and the Immune System.

Authors:  Chris Carter
Journal:  Int J Alzheimers Dis       Date:  2011-12-29

8.  What does complement do in Alzheimer's disease? Old molecules with new insights.

Authors:  Yong Shen; Libang Yang; Rena Li
Journal:  Transl Neurodegener       Date:  2013-10-12       Impact factor: 8.014

Review 9.  Innate immunity and neuroinflammation.

Authors:  Abhishek Shastri; Domenico Marco Bonifati; Uday Kishore
Journal:  Mediators Inflamm       Date:  2013-06-15       Impact factor: 4.711

10.  Microglia, Alzheimer's disease, and complement.

Authors:  Helen Crehan; John Hardy; Jennifer Pocock
Journal:  Int J Alzheimers Dis       Date:  2012-08-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.